New trial aims to halt spread of aggressive prostate cancer with precision radiation
NCT ID NCT07426094
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This clinical trial is for men with prostate cancer that has spread to nearby pelvic lymph nodes but not further. It compares two radiation strategies: one that gives a higher dose to the prostate only, and another that boosts both the prostate and the affected lymph nodes. All participants receive whole-pelvis radiation and hormone therapy. The goal is to see which approach better prevents the cancer from spreading to distant parts of the body.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Ultrahypofractionated whole-pelvis radiotherapy with optional prostate boost (via brachytherapy or SBRT) and nodal boost
What this could lead to
If successful, this trial could show the best way to intensify radiotherapy for node-positive prostate cancer, potentially improving metastasis-free survival and guiding future treatment standards.
What could go wrong
This is an early-to-mid-stage trial (phase II/III) with 1600 participants, and results may not confirm superiority of one approach. Long-term androgen deprivation therapy is required, and side effects from intensified radiation could be significant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Affidea Nu-Med, Center of Oncological Diagnostics and Therapy
RECRUITINGZamość, Lublin Voivodeship, 22-400, Poland
Contact Phone: •••-•••-•••• Email: •••••@•••••